Pharmafile Logo
Pharmafocus logo
Advanced Search

Rozlytrek

Showing 3 posts of 3 posts found.

NICE greenlights Roche’s Rozlytrek for ROS1+ advanced non-small cell lung cancer

June 15, 2020
Sales and Marketing NICE, Roche, Rozlytrek, UK, lung cancer

Roche’s Rozlytrek (entrectinib) has secured recommendation for NHS use in England and Wales after NICE backed the drug in final …

News

Roche’s cancer drug Rozlytrek scores double approval from FDA

August 16, 2019
Medical Communications Cancer, Roche, Rozlytrek, lung cancer, oncology

The FDA has approved Roche’s Rozlytrek (entrectinib) as a treatment for adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). …

News

Roche secures world first with Japanese Rozlytrek approval in advanced recurrent solid tumours

June 18, 2019
Manufacturing and Production, Sales and Marketing Cancer, Japan, Roche, Rozlytrek, pharma

Roche’s personalised cancer therapy Rozlytrek (entrectinib) has seen its first approval: the drug has been approved in Japan for the …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024